Henry Ji - 07 Sep 2022 Form 4 Insider Report for Sorrento Therapeutics, Inc.

Role
President, CEO and Chairman of the Board of Directors, Director
Signature
/s/ Henry Ji, Ph.D.
Issuer symbol
N/A
Transactions as of
07 Sep 2022
Net transactions value
+$215,584
Form type
4
Filing time
07 Sep 2022, 18:22:33 UTC
Previous filing
06 Sep 2022
Next filing
15 Nov 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SRNEQ Common Stock Purchase $179,349 +88,888 +1.9% $2.02* 4,765,805 07 Sep 2022 Direct F1
holding SRNEQ Common Stock 2,271,693 07 Sep 2022 See Footnote F2
holding SRNEQ Common Stock 40,000 07 Sep 2022 By spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SRNEQ Call Option (right to buy) Purchase $30,861 +759 $40.66* 759 07 Sep 2022 Common Stock 75,900 $12.00 By BioVintage, Inc.
transaction SRNEQ Call Option (right to buy) Purchase $5,374 +129 $41.66* 129 07 Sep 2022 Common Stock 12,900 $12.00 By BioVintage, Inc.
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.01 to $2.02, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased at each separate price.
F2 Shares are held in family trusts of which the Reporting Person is a co-trustee with his spouse.

Remarks:

President, CEO and Chairman of the Board of Directors